PharmTech Drug Digest 11.20
|Articles|June 3, 2014

Repligen Acquires Bioprocessing Business of Refine Technology

Repligen acquired Refine Technology and its Alternating Tangential Flow system for continuous bioprocessing.

Repligen acquired the business of Refine Technology, including Refine's Alternating Tangential Flow (ATF) System, a leading cell-retention device used to significantly increase product yield during the fermentation step of the biologic-drug manufacturing process. The acquisition strengthens Repligen's bioprocessing business by adding a profitable and highly complementary product line while expanding its direct sales presence worldwide.

The purchase involves a combination of $20.5 million in cash and 215,285 shares of Repligen common stock, for total upfront consideration of approximately $24.5 million. The agreement also includes contingent milestone payments of up to $8.75 million based on defined revenue targets through the year 2016, a capped royalty provision of up to $2.15 million for above-target sales during the same period. The company expects ATF System sales to add approximately $3.5-4.0 million in revenue for the remainder of the year 2014.

Source: Repligen


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.